Suppr超能文献

双相情感障碍、肥胖症与药物治疗相关的体重增加。

Bipolar disorder, obesity, and pharmacotherapy-associated weight gain.

作者信息

Keck Paul E, McElroy Susan L

机构信息

Division of Clinical Neuroscience, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0559, USA.

出版信息

J Clin Psychiatry. 2003 Dec;64(12):1426-35. doi: 10.4088/jcp.v64n1205.

Abstract

BACKGROUND

Bipolar disorder, overweight, and obesity are each national public health problems. Overweight and obesity also appear to be related to mood disorders, and patients with bipolar disorder, in particular, may be at greater risk for overweight and obesity than individuals in the general population. This risk may be due to factors associated with the illness itself and/or with medications used to treat bipolar disorder.

METHOD

We conducted a MEDLINE literature search of all English-language articles (1966-2002) using the keywords lithium, olanzapine, valproate, valproic acid, divalproex sodium, carbamazepine, lamotrigine, obesity, weight, and bipolar disorder. We augmented this search with manual review of relevant references. Our focus was on studies examining the prevalence of overweight and obesity in bipolar disorder, the risk and magnitude of weight gain associated with medications used to treat bipolar disorder, and the prevention and treatment of overweight and obesity in patients with bipolar disorder.

RESULTS

Forty-five studies were reviewed. Patients with bipolar disorder appear to be at greater risk than the general population for overweight and obesity. Comorbid binge-eating disorder; the number of depressive episodes; treatment with medications associated with weight gain, alone or in combination; excessive carbohydrate consumption; and low rates of exercise appear to be risk factors for weight gain and obesity in patients with bipolar disorder.

CONCLUSIONS

More research is required to identify the impact of specific risk factors for overweight and obesity in patients with bipolar disorder. These data could be used to develop better weight gain prevention and treatment programs for those with bipolar disorder. Therapeutic options include dietary counseling, use of mood stabilizers with lower propensities for weight gain, and combination pharmacotherapy with medications that have weight loss properties.

摘要

背景

双相情感障碍、超重和肥胖均为全国性公共卫生问题。超重和肥胖似乎也与情绪障碍有关,尤其是双相情感障碍患者,相较于普通人群,其超重和肥胖风险可能更高。这种风险可能归因于与疾病本身相关的因素和/或用于治疗双相情感障碍的药物。

方法

我们使用关键词锂盐、奥氮平、丙戊酸盐、丙戊酸、丙戊酸钠、卡马西平、拉莫三嗪、肥胖、体重和双相情感障碍,对MEDLINE中所有英文文章(1966 - 2002年)进行了文献检索。我们通过人工查阅相关参考文献对此次检索进行了补充。我们的重点是研究双相情感障碍中超重和肥胖的患病率、与用于治疗双相情感障碍的药物相关的体重增加风险及程度,以及双相情感障碍患者超重和肥胖的预防与治疗。

结果

共审查了45项研究。双相情感障碍患者超重和肥胖的风险似乎高于普通人群。共病的暴饮暴食症、抑郁发作次数、单独或联合使用与体重增加相关的药物进行治疗、碳水化合物摄入过多以及运动率低似乎是双相情感障碍患者体重增加和肥胖的风险因素。

结论

需要更多研究来确定双相情感障碍患者超重和肥胖的特定风险因素的影响。这些数据可用于为双相情感障碍患者制定更好的体重增加预防和治疗方案。治疗选择包括饮食咨询、使用体重增加倾向较低的心境稳定剂,以及与具有减肥特性的药物联合进行药物治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验